Verrica Pharmaceuticals Inc. Debt Securities, Available-for-sale, Amortized Cost
Verrica Pharmaceuticals Inc. (VRCA) had Debt Securities, Available-for-sale, Amortized Cost of $7.01 million as of 2022-09-30, per its 10-Q filed 2022-11-07.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2023-03-06
- 2022-09-30: Debt Securities, Available-for-sale, Amortized Cost $7.01M.
- 2022-06-30: Debt Securities, Available-for-sale, Amortized Cost $9.03M.
- 2022-03-31: Debt Securities, Available-for-sale, Amortized Cost $11.56M.
- 2021-12-31: Debt Securities, Available-for-sale, Amortized Cost $54.63M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2022-09-30 | $7.01M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $9.03M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $11.56M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $54.63M 10-K · filed 2023-03-06 |
| 2021-09-30 | $59.05M 10-Q · filed 2021-11-12 |
| 2021-06-30 | $65.42M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $43.58M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $54.78M 10-K · filed 2022-03-02 |
| 2020-09-30 | $54.68M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $30.66M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $33.88M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $52.76M 10-K · filed 2021-03-17 |
| 2019-09-30 | $60.45M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $58.86M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $58.84M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $79.56M 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |